Lord, Abbett & Co’s Definium Therapeutics DFTX Stock Holding History

Lord, Abbett & Co’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$36.5M	Buy	+958,635	New	+$40.4M	0.11%	197

Other funds holding DFTX

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Capital International Investors Los Angeles, California $483B AUM 27.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $60.6B AUM 33.98% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Lord, Abbett & Co's DFTX Position: Q3 2026 in Review

Lord, Abbett & Co opened a new position in Definium Therapeutics (DFTX) in Q3 2026: 958,635 shares worth $36.5M. The stake represents 0.11% of the portfolio and ranks #197 among its holdings.

203 funds tracked by Wall St. Rank hold DFTX as of Q3 2026.

Lord, Abbett & Co held 958,635 shares of Definium Therapeutics worth $36.5M as of Q3 2026.
Definium Therapeutics was a new Lord, Abbett & Co position in Q3 2026.
Definium Therapeutics made up 0.11% of Lord, Abbett & Co's portfolio in Q3 2026, its #197 holding.
203 funds tracked by Wall St. Rank held Definium Therapeutics as of Q3 2026.

Based on Lord, Abbett & Co's 13F filing for Q3 2026, filed 13 Nov 2026.